文献速递糖尿病

利司那肽与利拉鲁肽(短效与长效GLP-1受体激动剂)对2型糖尿病患者食管和胃功能的影响

Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes.
PubMed 文献 · Diabetes Care · 2020-07-09

57例2型糖尿病患者随机接受利司那肽或利拉鲁肽治疗10周,比较食管反流、食管动力、胃排空及胃酸分泌的变化。利司那肽使胃排空半衰期延长52分钟,利拉鲁肽延长25分钟;两者对食管反流和动力均无显著影响;GLP-1受体激动剂使胃酸度降低20.7%。

要点

  • 利司那肽使胃排空半衰期延长52分钟(95%CI 16,88),利拉鲁肽延长25分钟(95%CI 3,46)。
  • 利司那肽与利拉鲁肽在反流次数和DeMeester评分上无显著差异。
  • GLP-1受体激动剂使胃酸度显著降低20.7%(95%CI -40.6,-0.8)。

核心结论

  • 利司那肽对早餐后胃排空的抑制作用比利拉鲁肽更明显,但两者对食管反流或动力均无显著影响,GLP-1受体激动剂似乎轻度降低胃酸分泌。

研究设计与样本

  • 随机对照研究,57例2型糖尿病患者随机接受利司那肽或利拉鲁肽治疗10周,分析24小时食管下段pH监测的反流次数、食管下括约肌压力、胃排空(13C-辛酸钠呼气试验)和胃酸分泌(13C-碳酸钙呼气试验)较基线的变化。

主要发现

  • 胃排空半衰期在利司那肽组延长52分钟(Δ95%CI 16,88,P=0.0065),在利拉鲁肽组延长25分钟(95%CI 3,46,P=0.025)。
  • 反流次数利司那肽组为33.7±4.1 vs 利拉鲁肽组40.1±5.3(均值±标准误,P=0.17),DeMeester评分利司那肽组35.1±6.7 vs 利拉鲁肽组39.7±7.5(P=0.61),两种药物各自分析结果相似。
  • 食管动力和食管下括约肌功能的其他参数较基线无显著变化。
  • 胃酸度在GLP-1受体激动剂治疗下显著降低-20.7%(95%CI -40.6,-0.8,P=0.042)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Short-acting glucagon-like peptide 1 receptor agonists (GLP-1 RAs) decelerate gastric emptying more than long-acting GLP-1 RAs. Delayed gastric emptying is a risk factor for gastroesophageal reflux disease. We aimed to measure esophageal reflux and function as well as gastric emptying and acid secretion during treatment with short-acting (lixisenatide) and long-acting (liraglutide) GLP-1 RAs. RESEARCH DESIGN AND METHODS: A total of 57 subjects with type 2 diabetes were randomized to a 10-week treatment with lixisenatide or liraglutide. Changes from baseline in the number of reflux episodes during 24-h pH registration in the lower esophagus, lower esophagus sphincter pressure, gastric emptying (13C-sodium octanoate acid breath test), and gastric acid secretion (13C-calcium carbonate breath test) were analyzed. RESULTS: Gastric emptying half-time was delayed by 52 min (Δ 95% CI 16, 88) with lixisenatide (P = 0.0065) and by 25 min (3, 46) with liraglutide (P = 0.025). There was no difference in the number of reflux episodes (mean ± SEM 33.7 ± 4.1 vs. 40.1 ± 5.3 for lixisenatide and liraglutide, respectively, P = 0.17) or the extent of gastroesophageal reflux (DeMeester score) (35.1 ± 6.7 vs. 39.7 ± 7.5, P = 0.61), with similar results for the individual GLP-1 RAs. No significant changes from baseline in other parameters of esophageal motility and lower esophageal sphincter function were observed. Gastric acidity decreased significantly by -20.7% (-40.6, -0.8) (P = 0.042) with the GLP-1 RAs. CONCLUSIONS: Lixisenatide exerted a more pronounced influence on gastric emptying after breakfast than liraglutide. Neither lixisenatide nor liraglutide had significant effects on esophageal reflux or motility. Gastric acid secretion appears to be slightly reduced by GLP-1 RAs.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Quast DR, Schenker N, Menge BA, et al. Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes. Diabetes Care. 2020. PMID: 32647054. doi:10.2337/dc20-0720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。